A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten to undermine years of scientific progress. Lenacapavir, an injectable medication requiring only biannual administration, represents a potential paradigm shift in the global fight against HIV. However, significant reductions in international health funding have cast doubt on whether this […]
The post HIV breakthrough faces critical funding cuts appeared first on Rolling Out.
Leave a Reply